Reading TDOC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TDOC free→Reading TDOC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TDOC free→QuarterlyIQ Insights · TDOC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On April 29, 2026, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the first quarter of 2026. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective March 30, 2026, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Susan R. Salka as a director of the Company. Ms. Salka was additionally appointed to each of the audit committee and the compensation committee of the Board. The Board has determ…
Results of Operations and Financial Condition. On February 25, 2026, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the fourth quarter and full year 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective February 18, 2026, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Michael S. Smith as a director of the Company. Mr. Smith was additionally appointed to each of the audit committee and the nominating and corporate governance committee of the…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 8, 2026, Mr. Thomas G. McKinley notified Teladoc Health, Inc. (the “Company”) of his intention to retire from the Board effective as of February 20, 2026. Mr. McKinley has been a director of the Company since 2009 and the Company thanks him for his dedicated service. Mr. McKinley has indicated that he is retiring from the Board for pers…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 11, 2025, Mr. J. Eric Evans notified Teladoc Health, Inc. (the “Company”) of his intention not to stand for reelection at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”) and to retire from the Board effective as of the conclusion of the Annual Meeting. Mr. Evans has been a director of the Company since 2023 and…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 9, 2025, Teladoc Health, Inc. (the "Company" or "we") amended its 2023 Employment Inducement Incentive Award Plan (as amended, the “2023 Inducement Plan”) solely to increase the number of shares of common stock, par value $0.001 per share (“Common Stock”), reserved for issuance under the 2023 Inducement Plan by 1,780,000 shares, to a ne…
Results of Operations and Financial Condition. On October 29, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the third quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Results of Operations and Financial Condition. On October 23, 2025, Teladoc Health, Inc. (the “Company” or “we”) issued a press release announcing preliminary results for the quarter ended September 30, 2025. These financial results are preliminary, unaudited and subject to change in connection with the completion of the Company’s financial closing process and the preparation of its financial statements for the third quarter of 2025. In addition, the Company announced that it continues to exp…
of this Current Report is furnished herewith as Exhibit 99.1. The information furnished under this Item 7.01 (including Exhibit 99.1) of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements This…
Results of Operations and Financial Condition. On July 29, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the second quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Entry into a Material Definitive Agreement . On July 17, 2025 (the “Effective Date”), Teladoc Health, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative Agent”), issuing bank and swingline lender, and the lenders party thereto. The Credit Agreement provides for a five-year, $300 million senior secured revolving credit facility (the “Revolving Credit Facility”). The Company…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Teladoc Health, Inc. (the “Company”) was held on May 22, 2025. At the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Teladoc Health, Inc. 2023 Incentive Award Plan (the “Incentive Award Plan”) to increase the number of shares of the Company’…
Results of Operations and Financial Condition. On April 30, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the first quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
Results of Operations and Financial Condition. On February 26, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the fourth quarter and full year 2024. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.